A major pharmaceutical company has announced the successful completion of a plan to fully integrate its Biologics subsidiary, officially making... Read more
Category: Uncategorized
AstraZeneca Expands Amyloidosis Collaboration with Deal Potentially Reaching $780 Million
Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second... Read more
Major Funding Deal: Therapeutics Company Secures $275 Million Through Drug Royalty Agreement
A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The... Read more
Minimum Acceptance Threshold Met in Exchange Proposal Between Two Biotech Firms
(MAINZ, Germany, December 3, 2025) – The biotech firm BioNTech (Nasdaq: BNTX) recently announced that the minimum condition for its... Read more
A New Breakthrough in Duchenne Muscular Dystrophy Treatment: Promising Phase 3 Trial Results
A therapeutics company has announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial, evaluating the efficacy of... Read more
Strategic Alliance: French Pharmaceutical Group Partners with Major Drugstore Chain
A reputable pharmaceutical corporation from France, with over seven decades of experience in the research, production, and distribution of healthcare... Read more
Pharmaceutical Update: Regulatory Body Approves and Renews Nearly 600 Drug Licenses
The Pharmaceutical Management Agency under the Ministry of Health of Vietnam has announced a new list of approximately 600 drug... Read more
Expanding Horizons: The Growth Journey of a Private Healthcare Group
The establishment of a specialized obstetrics and gynecology facility in Can Tho led to the formation of a healthcare group... Read more
European Authorities Clear Novel Autoimmune Therapy for Myasthenia Gravis
The European Commission has granted authorization for nipocalimab, an immunoglobulin G (IgG) receptor antagonist developed by Johnson & Johnson, for... Read more









